{
    "clinical_study": {
        "@rank": "80817", 
        "acronym": "IMPACT", 
        "arm_group": {
            "arm_group_label": "cyclosporine 0.05% ophthalmic emulsion", 
            "arm_group_type": "Experimental", 
            "description": "Cyclosporine 0.05% ophthalmic emulsion (Restasis\u00ae) eye drops administered twice daily and carboxymethylcellulose-based lubricant eye drops (Refresh OPTIVE\u00ae Advanced) administered as needed for 6 months."
        }, 
        "brief_summary": {
            "textblock": "This study will evaluate the safety and efficacy of cyclosporine 0.05% ophthalmic emulsion\n      (Restasis\u00ae) in patients with dry eye disease."
        }, 
        "brief_title": "Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Dry Eye Syndromes", 
        "condition_browse": {
            "mesh_term": [
                "Dry Eye Syndromes", 
                "Keratoconjunctivitis Sicca"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  History of dry eye in both eyes\n\n          -  Willing to use eye drops for dry eye symptoms\n\n        Exclusion Criteria:\n\n          -  Anticipate wearing contact lenses during the study\n\n          -  Laser-assisted in situ keratomileusis (LASIK) surgery within the past 12 months\n\n          -  Any ocular and/or lid surgeries within the past 6 months\n\n          -  Cataract surgery in either eye\n\n          -  Current or anticipated use of temporary punctal plugs during the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 22, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02121847", 
            "org_study_id": "GMA-RES-014-001"
        }, 
        "intervention": [
            {
                "arm_group_label": "cyclosporine 0.05% ophthalmic emulsion", 
                "description": "Cyclosporine 0.05% ophthalmic emulsion (Restasis\u00ae) eye drops administered twice daily for 6 months.", 
                "intervention_name": "cyclosporine 0.05% ophthalmic emulsion", 
                "intervention_type": "Drug", 
                "other_name": "Restasis\u00ae"
            }, 
            {
                "arm_group_label": "cyclosporine 0.05% ophthalmic emulsion", 
                "description": "Carboxymethylcellulose-based lubricant eye drops (Refresh OPTIVE\u00ae Advanced) administered as needed for 6 months.", 
                "intervention_name": "carboxymethylcellulose-based lubricant eye drops", 
                "intervention_type": "Drug", 
                "other_name": "Refresh OPTIVE\u00ae Advanced"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Tetrahydrozoline", 
                "Carboxymethylcellulose Sodium", 
                "Cyclosporins", 
                "Cyclosporine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 22, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Andover", 
                    "country": "United States", 
                    "state": "Massachusetts"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "overall_contact": {
            "email": "clinicaltrials@allergan.com", 
            "last_name": "Allergan Inc."
        }, 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Visual Function Reading Speed", 
            "safety_issue": "No", 
            "time_frame": "Month 6"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02121847"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Tear Film Break-up Time (TFBUT)", 
                "safety_issue": "No", 
                "time_frame": "Month 6"
            }, 
            {
                "measure": "Ocular Protection Index", 
                "safety_issue": "No", 
                "time_frame": "Month 6"
            }, 
            {
                "measure": "Conjunctival Redness Score", 
                "safety_issue": "No", 
                "time_frame": "Month 6"
            }, 
            {
                "measure": "Ocular Surface Staining Score", 
                "safety_issue": "No", 
                "time_frame": "Month 6"
            }, 
            {
                "measure": "Blink Rate", 
                "safety_issue": "No", 
                "time_frame": "Month 6"
            }, 
            {
                "measure": "Ocular Symptoms Questionnaire Score", 
                "safety_issue": "No", 
                "time_frame": "Month 6"
            }
        ], 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}